2128. Participation in HIV Care Is Associated with Decreased Time to Cancer Treatment in those with HIV-associated Malignancy in Uganda
Session: Poster Abstract Session: HIV: Cancers, HPV, Dysplasia
Saturday, October 29, 2016
Room: Poster Hall
  • U015_IDWeekPoster.pdf (589.4 kB)
  • Background:

    Co-morbid HIV infection is common among cancer patients in Uganda and is associated with a more than 2-fold risk of death. At the Uganda Cancer Institute (UCI) the country’s national cancer hospital, nearly two-thirds of patients with HIV-Associated Malignancies (HIVAM) present with late stage cancer. Understanding the care cascade and barriers to cancer treatment among patients with HIVAM could guide interventions to promote earlier detection and treatment.


    Patients aged ≥18 with confirmed diagnoses of both cancer and HIV who registered at the UCI between June 1, 2015 and January 31, 2016 were included in this study. Consenting participants had a one-time structured interview and phlebotomy for CD4 T cell count. We used ANOVA, t-tests, and linear regression to compare quantitative responses.


    We enrolled 101 patients; 52% were female, median age 41, 69% had an AIDS-defining cancer (ADC) and the remainder had a non-ADC such as breast or lung cancer.  Median time from cancer symptoms to arrival at the UCI was 207 days (IQR 117-270, Figure). HIV had been diagnosed in 73% before cancer symptom onset and 27% were diagnosed with HIV during cancer work-up. 61% were on antiretroviral therapy (ART) prior to cancer symptoms. Receiving HIV care was associated with decreased time to seeking care for cancer symptoms (30 vs. 106 days, p=0.002) and decreased time to cancer diagnosis (138 vs. 208 days, p=0.02). Being on ART prior to cancer symptoms was associated with a shorter total time to cancer treatment (189 days, IQR 104-333) and remained significant in multivariate analyses (p=0.01). Gender, age, CD4 count, ADC, distance to HIV care, and distance to the UCI did not predict time to cancer care.  ART interruption, often due to cancer care, was common among participants.


    Persons receiving HIV care, especially those on ART, moved more quickly through the cancer care cascade than HIV+ cancer patients whose HIV had not been diagnosed or treated when cancer developed. It is likely that routine engagement with the health care system facilitates diagnosis and referral for cancer treatment in a country where access to primary care is limited. Delayed diagnosis and lack of coordinated care present barriers to patients with HIVAM in sub-Saharan Africa.


    Daniel Low, BA, School of Medicine, University of Washington, Seattle, WA, Jackson Orem, MBChB, MMed, PhD, Makerere University, Kampala, Uganda; Uganda Cancer Institute, Kampala, Uganda, Corey Casper, MD, MPH, FIDSA, University of Washington, Seattle, WA, Warren Phipps, MD, MPH, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Division of Allergy and Infectious Disease, University of Washington, Seattle, WA and Rachel Bender Ignacio, MD MPH, Medicine/Allergy and Infectious Disease, University of Washington, Seattle, WA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA


    D. Low, None

    J. Orem, None

    C. Casper, Janssen Pharmaceuticals: Grant Investigator and Scientific Advisor , Research grant and Research support
    Roche: Grant Investigator and Scientific Advisor , Grant recipient

    W. Phipps, None

    R. Bender Ignacio, None

    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.